Cargando…
Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
Most patients infected with SARS-CoV-2 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics, and the association between antibody levels, clinical symptoms, and disease phase in these patients have not yet been fully defined. Confirmed SARS-CoV-2 patients and their h...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253728/ https://www.ncbi.nlm.nih.gov/pubmed/34215811 http://dx.doi.org/10.1038/s41598-021-93175-y |
_version_ | 1783717575418445824 |
---|---|
author | Efrati, Shai Catalogna, Merav Abu Hamed, Ramzia Hadanny, Amir Bar-Chaim, Adina Benveniste-Levkovitz, Patricia Strugo, Refael Levtzion-korach, Osnat |
author_facet | Efrati, Shai Catalogna, Merav Abu Hamed, Ramzia Hadanny, Amir Bar-Chaim, Adina Benveniste-Levkovitz, Patricia Strugo, Refael Levtzion-korach, Osnat |
author_sort | Efrati, Shai |
collection | PubMed |
description | Most patients infected with SARS-CoV-2 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics, and the association between antibody levels, clinical symptoms, and disease phase in these patients have not yet been fully defined. Confirmed SARS-CoV-2 patients and their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load and serology analysis every ten days. A total of 1334 serum samples were collected from 135 patients and analyzed using three assays for IgG-N, IgG-S and IgM antibodies. Of the study participants, 97% were seropositive during the study, and two distinct clusters were identified. These clusters were significantly different in their inflammatory related symptoms. Peak IgG-S was 40.0 AU/ml for the non-inflammatory cluster and 71.5 AU/ml for the inflammatory cluster (P = 0.006), whereas IgG-N peaks were 4.3 and 5.87 (P = 0.023) respectively. Finally, a decision tree model was designed to predict the disease phase based on the serological titer levels, and had an overall accuracy of 80.7%. The specific profile of seroconversion and decay of serum antibodies can be used to predict the time-course from the acute infection. |
format | Online Article Text |
id | pubmed-8253728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82537282021-07-06 Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients Efrati, Shai Catalogna, Merav Abu Hamed, Ramzia Hadanny, Amir Bar-Chaim, Adina Benveniste-Levkovitz, Patricia Strugo, Refael Levtzion-korach, Osnat Sci Rep Article Most patients infected with SARS-CoV-2 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics, and the association between antibody levels, clinical symptoms, and disease phase in these patients have not yet been fully defined. Confirmed SARS-CoV-2 patients and their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load and serology analysis every ten days. A total of 1334 serum samples were collected from 135 patients and analyzed using three assays for IgG-N, IgG-S and IgM antibodies. Of the study participants, 97% were seropositive during the study, and two distinct clusters were identified. These clusters were significantly different in their inflammatory related symptoms. Peak IgG-S was 40.0 AU/ml for the non-inflammatory cluster and 71.5 AU/ml for the inflammatory cluster (P = 0.006), whereas IgG-N peaks were 4.3 and 5.87 (P = 0.023) respectively. Finally, a decision tree model was designed to predict the disease phase based on the serological titer levels, and had an overall accuracy of 80.7%. The specific profile of seroconversion and decay of serum antibodies can be used to predict the time-course from the acute infection. Nature Publishing Group UK 2021-07-02 /pmc/articles/PMC8253728/ /pubmed/34215811 http://dx.doi.org/10.1038/s41598-021-93175-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Efrati, Shai Catalogna, Merav Abu Hamed, Ramzia Hadanny, Amir Bar-Chaim, Adina Benveniste-Levkovitz, Patricia Strugo, Refael Levtzion-korach, Osnat Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients |
title | Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients |
title_full | Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients |
title_fullStr | Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients |
title_full_unstemmed | Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients |
title_short | Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients |
title_sort | early and long term antibody kinetics of asymptomatic and mild disease covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253728/ https://www.ncbi.nlm.nih.gov/pubmed/34215811 http://dx.doi.org/10.1038/s41598-021-93175-y |
work_keys_str_mv | AT efratishai earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT catalognamerav earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT abuhamedramzia earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT hadannyamir earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT barchaimadina earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT benvenistelevkovitzpatricia earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT strugorefael earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT levtzionkorachosnat earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients |